doi: 10.1186/s40880-017-0182-y
The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
Young Saing Kim, Chi-Young Jeong, Haa-Na Song, Tae Hyo Kim, Hong Jun Kim, Young-Joon Lee and Soon Chan Hong
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center
[Abstract]
Background
The optimal treatment strategy for biliary tract cancer (BTC) after curative-intent resection remains controversial. The purpose of this study was to evaluate the efficacy of fluoropyrimidine-based adjuvant chemotherapy for BTC patients undergoing microscopically margin-negative (R0) resection.
Methods We retrospectively analyzed the clinical data of BTC patients who underwent curative-intent R0 resection. Patients were eligible if they received either fluoropyrimidine-based adjuvant chemotherapy or observation after R0 resection.
Results A total of 153 patients were included. In the entire patient cohort, no significant differences were observed in 5-year overall survival (OS) rates (48.4% vs. 39.6%, P = 0.439) or 3-year recurrence-free survival (RFS) rates (49.1% vs. 39.5%, P = 0.299) between patients who received fluoropyrimidine-based adjuvant chemotherapy or observation. However, for patients with stages II and III BTC, chemotherapy significantly improved 5-year OS rate (52.4% vs. 35.6%, P = 0.002) and 3-year RFS rate (55.5% vs. 39.1%, P = 0.021) compared with observation.
Conclusion Fluoropyrimidine-based adjuvant chemotherapy may prolong the survival of patients with stages II and III BTC after R0 resection.
Methods We retrospectively analyzed the clinical data of BTC patients who underwent curative-intent R0 resection. Patients were eligible if they received either fluoropyrimidine-based adjuvant chemotherapy or observation after R0 resection.
Results A total of 153 patients were included. In the entire patient cohort, no significant differences were observed in 5-year overall survival (OS) rates (48.4% vs. 39.6%, P = 0.439) or 3-year recurrence-free survival (RFS) rates (49.1% vs. 39.5%, P = 0.299) between patients who received fluoropyrimidine-based adjuvant chemotherapy or observation. However, for patients with stages II and III BTC, chemotherapy significantly improved 5-year OS rate (52.4% vs. 35.6%, P = 0.002) and 3-year RFS rate (55.5% vs. 39.1%, P = 0.021) compared with observation.
Conclusion Fluoropyrimidine-based adjuvant chemotherapy may prolong the survival of patients with stages II and III BTC after R0 resection.
Chinese Journal of Cancer 2017, Volume: 36, Issue 5
[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)
[Google Scholar]
Cite this article
Young Saing Kim, Chi-Young Jeong, Haa-Na Song, Tae Hyo Kim, Hong Jun Kim, Young-Joon Lee and Soon Chan Hong. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection. Chin J Cancer. 2017, 36:9. doi:10.1186/s40880-017-0182-y
Export citations
EndNote
[ Html full-text / Citation export] (BioMed Central)
[Google Scholar]
Cite this article
Young Saing Kim, Chi-Young Jeong, Haa-Na Song, Tae Hyo Kim, Hong Jun Kim, Young-Joon Lee and Soon Chan Hong. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection. Chin J Cancer. 2017, 36:9. doi:10.1186/s40880-017-0182-y
Export citations
EndNote
SHARE THIS ARTICLE
Comments:
